Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs.


Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
02 2021
Historique:
accepted: 31 10 2020
pubmed: 26 11 2020
medline: 18 9 2021
entrez: 25 11 2020
Statut: ppublish

Résumé

Assessing the societal perspective in economic evaluations of new interventions requires estimates of indirect non-medical costs caused by the disease. Different methods exist for measuring the labor input function as a surrogate for these costs. They rarely specify the effect of health on labor and who gains and who loses money. Social accounting matrix (SAM) is an established framework that evaluates public policies with multiple perspectives that could help. We evaluated the use of a modified SAM to assess money flows between different economic agents resulting in economic transactions following policy changes of medical interventions. We compared conventional methods of measuring indirect non-medical costs related to rotavirus vaccination in the Netherlands with a modified SAM framework. To compare the outcome of each method, we calculated returns on investment (ROI) as the net amount of money per euro invested in the vaccine. One-way and probabilistic sensitivity analyses were carried out for each method, focusing on critical variables with the largest impact on indirect cost estimates. The ROI was higher for the modified SAM (1.33) than for the conventional methods assessing income calculations (range - 0.178 to 1.22). Probabilistic sensitivity analyses showed wide distributions in the ROI estimates, with variation in the variable impact on the indirect cost results per method selected. In contrast to conventional methods, the SAM approach provides detailed and comprehensive assessments of the impact of new interventions on the indirect non-medical costs and the financial interactions between agents, disclosing useful information for different stakeholders.

Sections du résumé

BACKGROUND
Assessing the societal perspective in economic evaluations of new interventions requires estimates of indirect non-medical costs caused by the disease. Different methods exist for measuring the labor input function as a surrogate for these costs. They rarely specify the effect of health on labor and who gains and who loses money. Social accounting matrix (SAM) is an established framework that evaluates public policies with multiple perspectives that could help.
OBJECTIVES
We evaluated the use of a modified SAM to assess money flows between different economic agents resulting in economic transactions following policy changes of medical interventions.
METHODS
We compared conventional methods of measuring indirect non-medical costs related to rotavirus vaccination in the Netherlands with a modified SAM framework. To compare the outcome of each method, we calculated returns on investment (ROI) as the net amount of money per euro invested in the vaccine. One-way and probabilistic sensitivity analyses were carried out for each method, focusing on critical variables with the largest impact on indirect cost estimates.
RESULTS
The ROI was higher for the modified SAM (1.33) than for the conventional methods assessing income calculations (range - 0.178 to 1.22). Probabilistic sensitivity analyses showed wide distributions in the ROI estimates, with variation in the variable impact on the indirect cost results per method selected.
CONCLUSIONS
In contrast to conventional methods, the SAM approach provides detailed and comprehensive assessments of the impact of new interventions on the indirect non-medical costs and the financial interactions between agents, disclosing useful information for different stakeholders.

Identifiants

pubmed: 33236330
doi: 10.1007/s40273-020-00978-4
pii: 10.1007/s40273-020-00978-4
pmc: PMC7867525
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

257-269

Subventions

Organisme : Medical Research Council
ID : MR/N013638/1
Pays : United Kingdom

Références

Value Health. 2018 Feb;21(2):124-130
pubmed: 29477389
Value Health. 2010 Jan-Feb;13(1):8-13
pubmed: 19883405
Appl Health Econ Health Policy. 2019 Oct;17(5):577-590
pubmed: 31098947
Palliat Med. 2017 Apr;31(4):323-337
pubmed: 27670418
Value Health. 2017 Feb;20(2):273-277
pubmed: 28237208
BMC Public Health. 2011 Jun 10;11:462
pubmed: 21663620
Int J Cardiol. 2013 Jun 5;166(1):68-71
pubmed: 22018513
Int J Technol Assess Health Care. 2011 Jan;27(1):71-6
pubmed: 21262069
Cancer. 2001 Feb 15;91(4):841-53
pubmed: 11241254
BMC Med. 2018 Sep 10;16(1):168
pubmed: 30196794
J Epidemiol Community Health. 2017 Aug;71(8):827-834
pubmed: 28356325
Vaccine. 2019 Mar 14;37(12):1692-1701
pubmed: 30661834
Hum Vaccin Immunother. 2013 Jun;9(6):1272-88
pubmed: 23571226
Health Econ Policy Law. 2016 Oct;11(4):415-32
pubmed: 26906561
Pharmacoeconomics. 2013 Jul;31(7):537-49
pubmed: 23620213
Lancet Glob Health. 2014 May;2(5):e251-2
pubmed: 25103158
Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):603-612
pubmed: 31755345
Appl Health Econ Health Policy. 2018 Dec;16(6):765-778
pubmed: 30094591
Eur J Health Econ. 2016 May;17(4):391-402
pubmed: 25876834
Vaccine. 2008 Feb 20;26(8):1118-27
pubmed: 18215445
Vaccine. 2015 Apr 27;33(18):2097-107
pubmed: 25795258
BMJ Open. 2015 Jun 30;5(6):e007453
pubmed: 26129633
Popul Health Manag. 2011 Apr;14(2):93-8
pubmed: 21091370
J Mark Access Health Policy. 2014 Apr 10;2:
pubmed: 27226842
Vaccine. 2018 Apr 19;36(17):2243-2253
pubmed: 29576308

Auteurs

Baudouin Standaert (B)

HEBO bv, Antwerpen, Belgium. baudouin.standaert@skynet.be.

Christophe Sauboin (C)

The University Medical Center Groningen, Groningen, The Netherlands.
Boehringer Ingelheim, Global Market Access Excellence, Ingelheim am Rhein, Germany.

Quentin J Leclerc (QJ)

Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.

Mark P Connolly (MP)

Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH